Clinical trials: Chronic Kidney Disease - Stage V
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis)
Blood Pressure Lowering in Dialysis (BOLD) Trial
Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis.
- Conditions
- Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
- Trial name
- BOLD (NCT03459807)
- Testing
- Anti-Hypertensive medications, Dry Weight Adjustment
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
End Stage Renal Disease
Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease
National Kidney Foundation guidelines recommend a dietary protein intake of 1.2 grams per kilogram per day (g/kg/d) in hemodialysis patients.
- Trial name
- NCT00566670
- Where
- 2 sites in United States
- Volunteers
- 145 people
- Sponsor
- University of Utah
Chronic Kidney Disease 5D
Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.
This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease…
- Trial name
- NCT07666815
- Testing
- Group A with creatine monohydrate, Group C Intradialytic Exercise Program, Comparison group D Hemodialysis
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pedro Julian Flores Moreno
Chronic Kidney Disease Stage 5 on Dialysis, Chronic Kidney Disease Stage 5 With Transplant
Vaccination Against COVID-19 in Chronic Kidney Disease
This is a prospective, multi-center, observational study that will enroll patients receiving dialysis (hemodialysis or peritoneal dialysis) or patients with kidney transplantation who will be vaccinated against COVID-19.
- Conditions
- Chronic Kidney Disease Stage 5 on Dialysis, Chronic Kidney Disease Stage 5 With Transplant, Vaccine Response Impaired
- Trial name
- NCT04743947
- Testing
- No intervention; observational study
- Where
- 5 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Chronic Kidney Disease Stage 5 on Dialysis
Inspiratory Muscle Training for Chronic Kidney Disease Patients on Hemodialysis
Chronic Kidney Disease (CKD) is a global public health problem with an increasing prevalence and incidence, poor prognosis, and high costs.
- Trial name
- NCT05241652
- Testing
- Inspiratory Muscle Training with an intensity of 50% MIP, Inspiratory Muscle Training with an intensity of 10% MIP
- Where
- Indonesia
- Volunteers
- 32 people
- Sponsor
- Universitas Padjadjaran
Chronic Kidney Disease, Dialysis
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00772382
- Testing
- MCI-196
- Where
- 21 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Tanabe Pharma Corporation
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Chronic Kidney Disease Stage 5 (CKD5) patients receiving maintenance hemodialysis are at an increased risk for developing bloodstream infections.
- Trial name
- NCT02392208
- Testing
- Telavancin, Pharmacokinetic Blood Sampling
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients
Aims: The investigators' primary objective is to assess both perceived and actual disease knowledge in local pre-dialysis Chronic Kidney Disease (CKD) patients.
- Conditions
- Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
- Trial name
- NCT01509716
- Where
- Singapore
- Volunteers
- 400 people
- Sponsor
- National University of Singapore
Chronic Kidney Disease Stage 5, End Stage Renal Disease
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the…
- Trial name
- VIEWER (NCT05726526)
- Testing
- VIEWER virtual care platform
- Where
- 5 sites in Canada
- Volunteers
- 340 people
- Sponsor
- University of Manitoba
Chronic Kidney Disease 5D, Chronic Kidney Disease Stage 5
Kidney Transplant Improvement Through New Exercise Training to Increase Capacity
The goal of this clinical trial is to learn if a home-based exercise program can be safely and feasibly used to improve physical activity and physical function in adults waiting for a kidney transplant.
- Conditions
- Chronic Kidney Disease 5D, Chronic Kidney Disease Stage 5, Kidney Failure, Kidney Failure,Chronic
- Trial name
- KINETIC (NCT07446296)
- Testing
- Exercise Rehabilitation Program with Physical Activity Tracker, Active control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Chronic Kidney Diseases Stage 5
Dietary and Dialysate Sodium Reduction on Body Fluid Volume and Inflammatory State in Hemodialysis Patients
Objective: To evaluate the influence of dietary sodium reduction on body fluid volume and inflammatory state in hemodialysis (HD) patients. Design: Prospective controlled randomized study.
- Trial name
- NCT01458808
- Testing
- Dietary sodium restriction, Dialysate sodium concentration reduction
- Volunteers
- 59 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B
Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function.
- Conditions
- Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B, Chronic Kidney Disease Stage 5, Diabetes Mellitus
- Trial name
- Fluo-AKI (NCT06760650)
- Testing
- Fluorescein angiography
- Where
- Lebanon
- Volunteers
- 35 people
- Sponsor
- Saint-Joseph University
Chronic Kidney Diseases, Chronic Disease
Controlling Hypertension Through Education and Coaching in Kidney Disease
Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching…
- Conditions
- Chronic Kidney Diseases, Chronic Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe)
- Trial name
- CHECK-D (NCT04087798)
- Testing
- Control-EDI, Intervention-EDI, Health coaching
- Where
- 11 sites in United States
- Volunteers
- 320 people
- Sponsor
- University of Michigan
Kidney Disease
Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis
The objective of this study is to determine the safety and efficacy of Zemplar® Capsule versus placebo, in decreasing elevated intact parathyroid hormone levels in chronic kidney disease stage 5 subjects with secondary…
- Trial name
- NCT00091975
- Testing
- Zemplar Capsule
- Where
- 16 sites in United States
- Volunteers
- 78 people
- Sponsor
- Abbott
Secondary Hyperparathyroidism
Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation
Eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in Russia. Planned therapy will be six months.
- Trial name
- NCT01401478
- Where
- 13 sites in Russia
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease Stage 5
Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease
The purpose of this study is to evaluate the efficacy of plant-protein diets for 12 weeks in patients with advanced chronic kidney disease.
- Trial name
- NCT05350098
- Testing
- Plant-protein Diets, Control Diets
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Osaka University
Chronic Kidney Disease, Dialysis
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00506441
- Testing
- MCI-196
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 245 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, End-stage Renal Disease
MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5
MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring…
- Conditions
- Chronic Kidney Disease, End-stage Renal Disease, Anaemia
- Trial name
- MONITOR-CKD5 (NCT01121237)
- Testing
- Recombinant human erythropoietin alfa (biosimilar)
- Where
- 95 sites in Austria, France and 8 more
- Volunteers
- 2,086 people
- Sponsor
- Sandoz
Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)
Open-label, pharmacodynamic, safety, pharmacokinetic and efficacy study of Lunacalcipol Injection.
- Conditions
- Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT), Hemodialysis (HD)
- Trial name
- 2007 (NCT01453634)
- Testing
- Lunacalcipol 180, Lunicalcipol 270
- Sponsor
- OPKO Health, Inc.